Muted quarter; what could be the reasons?
Posts tagged Value Pickr
Kovai Medical Center and Hospital – Health and Wealth (13-02-2024)
Yes, both the top and bottom lines have performed better than expected. This quarter’s margin improvement may be attributable to both the education and healthcare segments equally. This also suggests that the education sector had a disproportionate impact.
However, now that the fifth batch has entered, the education segment may not increase significantly in the next years. The only other levers in this segment are fee revision by the state government and the addition of MD seats (what does it take to obtain this permission?).
In Healthcare segment both the hospital’ number are given together. Difficult to know which part has improved. Given the numbers in the attachment, medical college bed occupancy and uses of other facilities is good now. But seems average stay days has to reduce. We cannot expect medical college bed to earn much but it being new facility there should be scope for further improvement (in additional to inflation) from here onward for few years.
clinical_material.pdf (266.9 KB)
With 250 crores of free cash flow currently, key monitorable will be how they invest it.
Disc: Invested
MOLD TEK PACKAGING—dividend plus growth (13-02-2024)
@Raj7800 how did you assume 400 rs/kg? Did the management provide?
IREDA: Renewable Energy Powerhouse (13-02-2024)
All these developments notwithstanding, the best time to add Ireda would be when it corrects another 30-50% from here (it has already corrected 25% from the top). If you are buying a financial services company at 7-8x price to book and hoping to make returns you need to be extremely lucky.
Bajaj Fin, a gold standard in NBFC space, was trading at 10 p/b in October 2021. Stock has since been in a time correction giving negative return. Same goes for Kotak or HDFC bank. Nothing wrong with their fundamentals or earning performances. It’s just that their stocks ended up on wrong side of the valuations.
Supriya Lifescience Ltd – pure play API (13-02-2024)
Looks like product mix getting sold is changed for Supriya Life Sciences, as a result they are confident that cyclicality of reduced sales in first half of year would not be same going forward, as guided by management.
They are now targeting Latin America markets and aiming overall 28-30% EBIDTA margins.
20 percent overall revenue growth expectation remains same.
I see that with capacity utilization more than 2.5 times, they should post more than 20 percent, however lets aim for 20 percent growth. Iam happy to take this with both hands.
Overall good improvement in PAT numbers, even though top level was flat.
Anesthetics has good margins
Zensar technologies (13-02-2024)
OFSS is a very good company with a strong parentage (Oracle) and high margin business. Valuation wise it trades at 20-25 forward multiples which to me is still quite reasonable if compared to Indian peer groups. For a long time it was ignored by the market (not sure if MNC parentage was a factor) but now stock is getting rerated following a very strong quarter.
Anant Raj Limited (13-02-2024)
In January 2024, every investor whether promoters, FII, DII has exited some amount of shares… Any Info?? why such thing happening?